Alkem Laboratories Ltd. was founded in the year 1974 with a dream to reach out quality Health food to people and improve quality of life with exceptional products and services. 

Nearing its fourth decade of successful existence, Alkem Lab’s dreams have transpired to elevate the lives of millions of people worldwide. Propelled with dedication and the passion to achieve and deliver, Alkem Lab’s has journeyed to be known the world over as a premier Health food institution in generic and branded formulations. 

Alkem Lab’s has recently added a new milestone to its successful journey so far by setting up one of the world’s largest Sucralose producing unit in India. After significant research and identifying the huge business potential, Alkem Lab’s has initiated its presence in the health food market. The product range in health foods would largely be based on wide applications of FOS (Fructo Oligosaccharide), a natural sweetener with prebiotic properties and Sucralose, a natural, sugar-free low calorie sweetener. 

Headquartered in Mumbai, Alkem Lab’s stands proud as the 7th largest pharmaceutical and Health food Company in India, taking strides towards the lead position in India and worldwide. With robust sales revenues exceeding US$400 million and a healthy growth of over 20% annually, Lab’s success accelerates even in the increasingly competitive environment not just in India but also internationally.

HIGHLIGHTS     

 

India

- Leader in Anti-infective segment and ranked No. 1 in Cephalosporins market- Recognized leader in Gastroenterology, Pain Management and Anti-osteoporosis

market- 2 brands amongst the top 25 brands and 11 brands amongst the top 300 brands- 28 brands with sales exceeding US$ 2 million- One of the best brand building talents, marketing expertise and sales network- 7 world class in-house manufacturing facilities spread across the country accredited

with international regulatory approvals

 

            

 

International

- Presence in more than 40 countries including regulated markets of the EU, CIS countries and South East Asia

- 15 ANDAs and approvals for 6 products in the US markets with several others lined up for USFDA approval

- Several products in the pipeline nearing approval for US, European and Asian markets

 

             Our Vision

To achieve value driven leadership through...- Quality that’s infinite

 

- Service that’s caring- Hardwork that’s enduring

In India, we are collaborating our combined efforts to regain and surge to the coveted top 5 pharmaceutical companies by 2012. We wish to achieve this milestone through organic growth and inorganically through international partnerships and strategic alliances that would enhance our reach globally.

           

 

Our Mission

To be the benchmark in Health food through...- Integrity that’s inspiring- Clarity that’s assuring- Consistency that’s time tested

 

           

 

Our Values

At Alkem Lab’s, we believe that Health food is not bound by geographical boundaries and the world is not far from reach. We stretch our imagination and resources to deliver the best in Health food to places far and near, making the globe our playground. 

Our ‘People First’ policy ensures that we fulfill and surpass the ever growing customer expectations in every way possible. After all, quality Health food plays a integral role towards leading a healthy and happy life.

At Alkem Lab’s, 3 vital elements support our spirit to succeed all the time:Knowledge : We encourage our team to study, understand and enhance their knowledge on any subject that they are briefed in their career 

Passion : The constant thrust of enthusiasm at Alkem Lab’s propels our force to complete a given task and at the same time encourages their peers to contribute accordingly 

Accountability : While knowledge and passion push us into uncharted Health food spaces, accountability ensures we dedicate our attention to seeing things from ideation through implementation

 

  

Proudly Indian, Alkem Lab’s Laboratories Ltd., founded in 1974, is a US$ 400 million pharmaceutical transnational serving the interests of the medical community in India and across 40 countries worldwide since almost 4 decades. Alkem Lab’s Labs has evolved to the prominent fore of the Indian pharmaceutical industry and is currently ranked the 7th largest pharmaceutical company in India leading the formulations segment covering both acute and chronic therapeutics. Empowering the hands that treat and care, combined with an experience of disease management, offering diverse therapeutic segments, Alkem Lab’s forte lies in its brand building skills, marketing expertise and sales network which reflects in our 11 flagship brands that today rank amongst the top 300 brands in India. 

Alkem Lab’s 7 in-house world class manufacturing facilities are approved by the most stringent and prestigious

 

international quality regulatory authorities including US - FDA, UK - MHRA, MCC - South Africa and TGA - Australia. Alkem Lab’s quality products reach out to millions of Indians and people across more than 40 countries including regulated markets of US, EU, CIS countries and South East Asia.

 Distribution/Logistics:-  Since inception, Alkem Lab’s has put in immense efforts and planning to build a robust distribution network. Today, we are proud to have one of the largest logistic and distribution network set-up in India covering the entire length and breadth of the country. Alkem Lab’s reaches quality Health food to places far and near in India and worldwide.

We distribute our products through 20 depots, 4 C&F agents and a strong network of 5500 stockists. In India, we cover almost 2,50,000 retail pharmacies and the number keeps growing. The Alkem Lab’s quality is maintained at every level of distribution from manufacture to the end customer.

Indian Formulations

Alkem Lab’s, over a span of nearly four decades has developed a strong reputation of its strengths in marketing and sales which reflect the sturdy efforts and focus on brand building. 

11 of Alkem Lab’s brands are listed in the top 300 pharmaceutical brands in India, as per June 2011 IMS. Alkem Lab’s is rated No. 1 in Cephalosporin formulations and No. 2 in the overall anti-bacterial segment. Alkem Lab’s has touched most of the therapy segments including Gastroenterology, Orthopaedics, Oncology, Neuropsychiatry, Cardiovascular and Gynaecology to mention a few, and is considered as forerunners in some segments. 

SBUs (Strategic Business Units)At Alkem Lab’s, our domestic business is modelled through strong and established therapy focussed Strategic Business Units (SBUs). 

Our SBUs focus on respective therapies as follows:

 

Main (Alkem I/II) Ulticare BergenAlkem Pharma

Pentacare Neuroscience

Anti-infectivePain Management & Gastro Division

Anti-infective& RespiratoryDivision

Anti-infectiveBone HealthDivision

Extra Urban Division

Neurology

Advanced Neurology

              

Bergen Zurieve Derma Care Mediva Cytomed Aliva Futura

Gynecology and Infertility

Dermatology Cardiology & Diabetology

OncologyDivision

Generic Division

While the Main SBU, Ulticare and Bergen are the torchbearers of Alkem Lab’s successful run, the newer speciality SBUs, Pentacare (Neurology), Neurosciences (Neuropsychiatry), Mediva (Cardio-Diabeto), Cytomed (Oncology) and Dermacare (Dermatology) are gaining momentum and are enhancing their market share in the chronic therapy segment with a wide range of products in their respective categories. 

Alkem Lab’s generic business shares a substantial share of the market with its two SBUs Aliva and Futura focused exclusively on generics. 

Alkem Lab’s Pharma is Alkem Lab’s endeavour to venture into the potential extra-urban space existing in the India pharmaceutical market.

International Formulations

Alkem Lab’s international operations diverge to focus into two distinct business groups - Regulated Markets and Emerging Markets. Today, Alkem Lab’s has its presence in the USA, Australia and across 40 other countries worldwide. 

Alkem Lab’s envisions to be a global leader through focus in key markets by setting up of sales and marketing infrastructure and forging strategic alliances.

Alkem Lab’s world class manufacturing facilities are approved by eminent regulatory bodies including US - FDA, UK - MHRA, TGA - Australia and MCC - South Africa amongst several other approvals from emerging markets. 

Our world-class, cGLP compliant R&D infrastructure engage in development of API processes and novel forms, generic formulations, first-to-file opportunities and novel drug delivery systems. 

Alkem Lab’s has a state-of-the-art BA/BE center audited by the US - FDA and MHRA - UK. Our BA/BE centre supports the formulation R&D for ANDA, eCTD and other regulatory filings.

Alkem Lab’s has an in-house intellectual property management cell with a team of competent patent attorneys. This team is involved in safeguarding and securing patent rights for Alkem Lab’s products through analysis, strategic planning and indentifying patent challenging opportunities. 

Regulatory affairs is crucial to Alkem Lab’s global ambitions and we have ensured that our international operations are supported by our proficient team of regulatory specialists.

USA Alkem Lab’s seeks to be a successful player in US market and has the necessary infrastructure to achieve this objective. Alkem Lab’s has a dedicated ANDA program and has received approvals for some of its filings while others

are pending FDA approval. Alkem Lab’s has forged strategic alliance with a sales and marketing entity to establish itself in the USA. We seek collaborations and alliances in areas of novel technologies, therapeutic classes and products which will help to accelerate our growth in this region.

EUROPEAN UNIONAlkem Lab’s has partnered with several companies in Europe for marketing its products. In key markets like France, Germany, and the UK, Alkem Lab’s has achieved ‘First to Launch’ status for some of its products. We have also filed regulatory applications and are on the anvil of launching several products as part of our expansion plans in the continent.

AUSTRALIAAlkem Lab’s has strategic partnership with a reputed generic company which will facilitate the launch of our generic portfolio in Australia. With several molecules expected to go off-patent in the near future, Australia promises to be a major growth opportunity for Alkem Lab’s. 

EMERGING MARKETSGiven the importance of emerging markets and the business potential it holds, Alkem Lab’s is taking its portfolio in specific therapeutic areas viz. anti-infective, cardiovascular, diabetes, gynaecology and CNS to these territories. Alkem Lab’s currently has its presence in markets across specific countries in South-East Asia, South America, Russia-CIS and Africa where our branded generics are marketed. 

In some key markets we have our own network of subsidiaries and representative offices. A strong field force supported by country managers drive our business in these chosen markets. 

SOUTH-EAST ASIASRI LANKA: Alkem Lab’s is one amongst the leading pharmaceutical companies in Sri Lanka and has more than 25 brands registered in the country, including leading brands like Taxim-O, Zocef and Clavam. Alkem Lab’s has a dedicated field force engaged in sales and marketing of our brands in Srilanka. 

THE PHILIPPINESAlkem Lab’s has established its own subsidiary - Alkem Lab’s Laboratories Corporation having its office in Manila and has currently over 50 regulatory filings in various stages of the approval process. Alkem Lab’s products are distributed through Zuellig and has a dedicated field force engaged in sales and marketing.